Morgan Stanley (NYSE:MS – Get Free Report) was downgraded by stock analysts at Hsbc Global Res from a “strong-buy” rating to a “hold” rating in a report issued on Tuesday,Zacks.com reports.
Other analysts have also issued reports about the company. UBS Group raised their price objective on Morgan Stanley from $102.00 to $112.00 and gave the company a “neutral” rating in a report on Tuesday, October 8th. The Goldman Sachs Group lifted their price target on Morgan Stanley from $106.00 to $121.00 and gave the stock a “neutral” rating in a research note on Thursday, October 17th. Wells Fargo & Company raised Morgan Stanley from an “underweight” rating to an “equal weight” rating and lifted their price target for the stock from $107.00 to $142.00 in a research note on Friday, November 15th. Barclays lifted their price target on Morgan Stanley from $121.00 to $135.00 and gave the stock an “overweight” rating in a research note on Thursday, October 17th. Finally, Jefferies Financial Group lifted their price target on Morgan Stanley from $120.00 to $135.00 and gave the stock a “buy” rating in a research note on Thursday, October 17th. Twelve analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Morgan Stanley presently has an average rating of “Hold” and an average target price of $115.63.
View Our Latest Report on Morgan Stanley
Morgan Stanley Stock Down 0.1 %
Morgan Stanley (NYSE:MS – Get Free Report) last posted its earnings results on Wednesday, October 16th. The financial services provider reported $1.88 EPS for the quarter, topping the consensus estimate of $1.57 by $0.31. Morgan Stanley had a return on equity of 12.58% and a net margin of 10.64%. The firm had revenue of $15.38 billion for the quarter, compared to analyst estimates of $14.27 billion. As a group, sell-side analysts anticipate that Morgan Stanley will post 7.32 earnings per share for the current year.
Insider Buying and Selling at Morgan Stanley
In other news, Director Stephen J. Luczo sold 60,000 shares of Morgan Stanley stock in a transaction on Thursday, October 17th. The stock was sold at an average price of $119.17, for a total value of $7,150,200.00. Following the completion of the sale, the director now directly owns 138,363 shares of the company’s stock, valued at approximately $16,488,718.71. The trade was a 30.25 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 0.24% of the company’s stock.
Institutional Investors Weigh In On Morgan Stanley
A number of institutional investors have recently modified their holdings of MS. Opal Wealth Advisors LLC acquired a new position in Morgan Stanley during the 2nd quarter worth $25,000. POM Investment Strategies LLC grew its stake in Morgan Stanley by 1,147.6% during the 2nd quarter. POM Investment Strategies LLC now owns 262 shares of the financial services provider’s stock worth $25,000 after purchasing an additional 241 shares in the last quarter. Bank & Trust Co acquired a new position in Morgan Stanley during the 2nd quarter worth $26,000. Northwest Investment Counselors LLC acquired a new position in Morgan Stanley during the 3rd quarter worth $26,000. Finally, Bbjs Financial Advisors LLC acquired a new position in Morgan Stanley during the 2nd quarter worth $29,000. 84.19% of the stock is owned by institutional investors and hedge funds.
Morgan Stanley Company Profile
Morgan Stanley, a financial holding company, provides various financial products and services to corporations, governments, financial institutions, and individuals in the Americas, Europe, the Middle East, Africa, and Asia. It operates through Institutional Securities, Wealth Management, and Investment Management segments.
Further Reading
- Five stocks we like better than Morgan Stanley
- Learn Technical Analysis Skills to Master the Stock Market
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- Investing in Construction Stocks
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- The 3 Best Blue-Chip Stocks to Buy Now
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Morgan Stanley Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Morgan Stanley and related companies with MarketBeat.com's FREE daily email newsletter.